{"filings":[{"id":815277,"accession_number":"0001628280-26-040034","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2026-06-03T10:47:08+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q4 rev $9.8B (+6.6% organic), non-GAAP EPS $1.55; dividend raised to $0.72","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $9.807B, +9.9% reported / +6.6% organic; GAAP EPS $0.96, non-GAAP EPS $1.55.","FY26 revenue $36.364B, +8.4% reported / +5.8% organic; GAAP EPS $3.73, non-GAAP EPS $5.53.","Dividend increased to $0.72/quarter ($2.88 annual), payable July 17, 2026; 49th consecutive annual increase.","FY27 guidance: organic revenue growth 6.75%-7.25%, non-GAAP EPS $5.90-$6.00.","Cardiac Ablation Solutions revenue +78% globally; Hugo RAS submission filed with FDA for general surgery/gyn."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":500076,"accession_number":"0001628280-26-035959","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2026-05-18T20:30:33+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medtronic neuroscience president Brett Wall to depart; Kweli Thompson named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brett Wall steps down as EVP & President, Neuroscience Portfolio; effective June 1, 2026.","Dr. Kweli Thompson moves from SVP & President, Cardiac Rhythm Management to succeed him.","Wall will remain an employee through September 1, 2026 to assist transition.","Severance consistent with Medtronic's executive severance practices per 2025 proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94094,"accession_number":"0001628280-26-027272","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Medtronic discloses unauthorized access to corporate IT systems; no patient or product impact found","summary_kind":"llm","event_type":"cyber","confidence":"medium","bullets":["Unauthorized third party accessed data in certain Medtronic corporate IT systems; incident discovered April 24, 2026.","Company confirms no impact to products, patient safety, customer connections, manufacturing, or financial reporting systems.","Corporate IT networks are separate from product and manufacturing networks; hospital customer networks are separate and managed by customers.","Investigation ongoing; working to identify any personal information accessed and will provide notifications and support as needed.","Medtronic does not currently expect a material impact on its business or financial results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106212,"accession_number":"0001613103-26-000005","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Medtronic cuts FY2026 EPS guidance on MiniMed charges; FDA clears MiniMed Flex pump","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA cleared MiniMed Flex insulin pump several months earlier than expected; smartphone-controlled.","One-time $157M charge in Q4 FY2026 due to Blackstone royalty arrangement; $0.08 EPS impact.","MiniMed IPO (10% stake) closed Mar 9; dilutes Medtronic EPS by $0.04 in Q4 FY2026.","FY2026 non-GAAP EPS guidance revised to $5.50-$5.54 from $5.62-$5.66.","FY2027 high single-digit EPS growth guidance unchanged; Blackstone earns mid-to-high single digit royalty on first two years of net sales."],"consensus_eps_estimate":null,"consensus_eps_actual":2.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":26557000000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106211,"accession_number":"0001628280-26-008300","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q3 FY2026: Revenue $9.02B (+6% organic), non-GAAP EPS $1.36 beats guidance; reiterates FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.89; non-GAAP diluted EPS $1.36, three cents above Q3 guidance mid-point.","Cardiovascular portfolio revenue $3.46B (+10.6% organic); Cardiac Ablation Solutions up 80% on pulsed field ablation.","Diabetes revenue $796M (+8.3% organic); Neuroscience $2.56B (+2.5% organic); Medical Surgical $2.17B (+2.7% organic).","Reiterates FY26 organic revenue growth ~5.5% and non-GAAP EPS guidance $5.62-$5.66, including ~$185M tariff impact.","Secured FDA clearances for Hugo robotic-assisted surgery and Stealth AXiS; CE Mark for Sphere-360; completed CathWorks and Anteris acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":2.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":26557000000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122497,"accession_number":"0001628280-25-052771","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q2 FY26: Revenue $9.0B (+5.5% organic), non-GAAP EPS $1.36 (+8%); raises FY26 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 organic revenue growth 5.5% (beat guidance midpoint by 75 bps); GAAP EPS $1.07 (+8%), non-GAAP EPS $1.36 (+8%).","Cardiovascular revenue $3.44B (+9.3% organic); Cardiac Ablation Solutions up 71% on PFA portfolio.","Raises FY26 organic revenue growth guidance to ~5.5% (from ~5.0%); non-GAAP EPS guidance to $5.62-$5.66.","Received FDA approval for Altaviva device for urge UI; CMS NCD for Symplicity hypertension procedure.","Diabetes revenue $757M (+7.1% organic); Hugo robotic surgery study met safety and effectiveness endpoints."],"consensus_eps_estimate":null,"consensus_eps_actual":1.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":17539000000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122496,"accession_number":"0001628280-25-048375","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Medtronic EVP Enterprise Operations Gregory Smith to retire Dec 2, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gregory L. Smith, EVP Enterprise Operations, notified retirement effective Dec 2, 2025 to join a private equity-held organization.","Retirement treatment of outstanding equity per proxy: accelerated unvested stock options, continued vesting of RSUs and PSUs.","No successor named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122495,"accession_number":"0001628280-25-045695","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Medtronic shareholders approve all proposals at 2025 AGM including director elections and bylaw amendments","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 director nominees elected; Craig Arnold received lowest support at 86.7% of votes cast.","Say-on-pay approved with 93.5% of votes cast in favor; ratification of PwC as auditor passed.","Shareholders approved amendment to Article 177 to capitalize non-distributable reserves and capital reduction to create distributable reserves.","Authority renewed to issue shares, opt out of pre-emption rights, and make overseas share purchases.","Advance notice provisions updated to strengthen shareholder proposal procedural requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139195,"accession_number":"0001193125-25-221819","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Medtronic issues €1.5B in senior notes; redeems €500M of 2025 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €750M of 2.950% Senior Notes due 2030 and €750M of 4.200% Senior Notes due 2045.","Net proceeds of ~€1.49B; proceeds to repay Medtronic Luxco's 0.000% and 2.625% notes due 2025.","On Sept 29, redeemed all €500M of Medtronic Luxco's 2.625% Senior Notes due 2025 at par plus accrued interest.","Notes are guaranteed by Medtronic plc and Medtronic Luxco; listed on NYSE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139194,"accession_number":"0001193125-25-205061","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Medtronic prices €1.5B dual-tranche note offering; redeems €500M 2.625% notes due 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issues €750M of 2.950% Senior Notes due 2030 and €750M of 4.200% Senior Notes due 2045.","Net proceeds intended to repay €500M of 2.625% Senior Notes due 2025 and €0% notes due 2025.","Redemption of 2.625% notes set for September 29, 2025, conditioned on closing of new notes.","Notes are fully and unconditionally guaranteed by Medtronic plc and Medtronic Global Holdings S.C.A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139193,"accession_number":"0001613103-25-000141","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Medtronic Q1 revenue $8.58B (+4.8% organic); raises FY26 EPS; adds 2 directors, forms new committees","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP EPS $0.81; non-GAAP EPS $1.26 (+2%), revenue $8.58B, organic growth 4.8%.","FY26 non-GAAP EPS guidance raised to $5.60-$5.66 from $5.50-$5.60; organic revenue growth ~5% reaffirmed.","Cardiac Ablation Solutions revenue +50% on pulsed field ablation strength; US +72%.","Board expanded to 13; John Groetelaars and William Jellison appointed as independent directors.","New Growth and Operations committees formed; Investor Day planned for mid-2026; engagement with Elliott Management."],"consensus_eps_estimate":null,"consensus_eps_actual":0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":8578000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156748,"accession_number":"0001613103-25-000094","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medtronic appoints Dr. Joon Lee as independent director, effective June 18, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 10 to 11 members; Dr. Lee appointed independent director.","Dr. Lee is CEO of Emory Healthcare, overseeing $7.7B revenue, 12 hospitals, 29,000+ employees.","He will serve on the Science & Technology and Compensation & Talent Committees.","Dr. Lee previously held executive roles at UPMC over 25 years, including EVP and President of Physician Services.","Appointment effective June 18, 2025; standard director compensation applies under existing policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156747,"accession_number":"0001613103-25-000078","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"Medtronic Q4 EPS $1.62 non-GAAP (+11%); to spin off Diabetes; dividend raised to $0.71","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Q4 FY25 revenue $8.93B (+5.4% organic); non-GAAP EPS $1.62 (+11% as reported, +16% constant currency).","Plans to spin off Diabetes business into standalone public company within 18 months via IPO/split-off; accretive to margins and EPS.","Dividend raised to $0.71/quarter ($2.84 annual) — 48th consecutive annual increase; payable July 11, 2025.","Sean Salmon departs as EVP Cardiovascular; Skip Kiil promoted to EVP/President Cardiovascular Portfolio; Michael Carter to lead CST.","FY26 guidance: ~5% organic revenue growth; non-GAAP EPS $5.50-$5.60 reflecting tariff uncertainty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175150,"accession_number":"0001613103-25-000034","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Medtronic principal accounting officer Kirk resigns; Blomquist named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer M. Kirk resigns as Global Controller & Principal Accounting Officer effective May 2, 2025 to become CEO of Exubrion Therapeutics.","Denise L. Blomquist, Assistant Global Controller, appointed as Global Controller & Principal Accounting Officer effective March 17, 2025.","Blomquist has 21-year Medtronic tenure; compensation aligns with similar officer positions under MIP, LTIP, and Change in Control Policy.","Kirk's departure not related to any disagreement over operations, policies, or practices; she will stay through May 2 for transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175149,"accession_number":"0001613103-25-000019","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q3 FY2025 revenue $8.3B, EPS $1.39 non-GAAP beat; organic growth 4.1%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.292B (+2.5% reported, +4.1% organic); GAAP EPS $1.01 (+2%), non-GAAP EPS $1.39 (+7%, above guidance).","Cardiovascular up 5% organic led by PFA (low-20s growth) and Micra (mid-20s growth); Diabetes up 10.4% organic.","Neuroscience up 5.2% organic (Neuromodulation low-double digit); Medical Surgical down 0.4% organic.","FY25 guidance reaffirmed: organic rev growth 4.75%-5%, non-GAAP EPS $5.44-$5.50.","CMS opened NCA for Renal Denervation; FDA approved additional PFA manufacturing site in Galway."],"consensus_eps_estimate":1.2416,"consensus_eps_actual":2.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":24610000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175148,"accession_number":"0001613103-25-000005","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medtronic appoints Thierry Pieton as CFO effective March 3, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thierry Pieton, former Renault Group CFO, named Medtronic CFO; reports to CEO Geoff Martha.","Salary: $850,000 base; 110% MIP target; $2M LTIP for FY2025 (PSU/stock option/RSU).","One-time cash bonus of $3M (3 installments) and $2.5M new hire RSU to replace foregone compensation.","Interim CFO Gary Corona becomes SVP Corporate Finance on Executive Committee after transition.","Compensation committee approved $1M RSU grant to Corona for interim CFO service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192088,"accession_number":"0001613103-24-000162","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q2 revenue $8.4B (+5.3%); raises FY25 organic growth and EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.99 (up 46% YoY); non-GAAP diluted EPS $1.26 (up 1% as reported, 8% constant currency).","Revenue $8.403B, organic growth 5.0%; driven by TAVR, PFA, leadless pacemakers, Diabetes, Spine, Neuromodulation.","FY25 organic revenue growth guidance raised to 4.75%-5% from 4.5%-5%; non-GAAP EPS guidance raised to $5.44-$5.50 from $5.42-$5.50.","Diabetes revenue $686M (+12.4% as reported, +11% organic) on continued adoption of MiniMed 780G AID system.","Cardiovascular portfolio revenue $3.102B (+6.1% as reported, +5.6% organic) with high-single digit growth in Structural Heart (Evolut FX+ TAVR launch)."],"consensus_eps_estimate":1.5946,"consensus_eps_actual":1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":16318000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192087,"accession_number":"0001613103-24-000151","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Medtronic shareholders elect all ten director nominees at 2024 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All ten director nominees elected with strong support; Geoffrey S. Martha received 943M for (94.6%).","Ratification of PwC as auditor for FY2025 passed with 1,008.7M for vs 107.7M against.","Advisory say-on-pay vote passed with 924.5M for (92.3% of votes cast excluding broker non-votes).","Shareholders approved renewal of Board authority to issue shares (1,094.7M for) and opt out of pre-emption rights.","Authorization for overseas market purchases of ordinary shares approved with 1,086.8M for votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208581,"accession_number":"0001613103-24-000140","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q1 FY25: revenue $7.9B (+2.8%), GAAP EPS $0.80, non-GAAP EPS $1.23; raises FY25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.915B (adjusted $8.004B), up 5.3% organic; GAAP EPS $0.80, non-GAAP EPS $1.23 (+8% constant currency).","Raises FY25 organic revenue growth guidance to 4.5%-5% (from 4-5%) and non-GAAP EPS guidance to $5.42-$5.50.","Cardiovascular $3.007B (+6.9% organic) driven by CRM and PFA; Neuroscience $2.317B (+5.3% organic) with Neuromodulation up low-double digits.","Diabetes $647M (+12.6% organic) on MiniMed 780G; Simplera CGM FDA approved, Abbott partnership for future integrated CGM.","Medical Surgical $1.996B (+1.0% organic) with SE low-single digit growth and ACM flat."],"consensus_eps_estimate":null,"consensus_eps_actual":0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":7915000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208580,"accession_number":"0001613103-24-000133","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K/A","filed_at":"2024-08-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Medtronic sets interim CFO Corona's compensation: $12,500 bi-weekly stipend, 8,966 RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bi-weekly cash stipend of $12,500 effective August 3, 2024.","Grant of 8,966 time-based RSUs vesting over two years (50% annually).","Annual base salary maintained at $500,000; target bonus unchanged at 70% of salary.","Long-term incentive grant of $1 million granted July 29, 2024 also unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226290,"accession_number":"0001613103-24-000076","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Medtronic CFO Karen Parkhill resigns; interim CFO Gary Corona appointed; FY2025 guidance reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Karen Parkhill will resign as EVP & CFO effective Aug 2, 2024, to become CFO of HP Inc.","Gary Corona, SVP Global FP&A, will serve as interim CFO upon Parkhill's departure.","Company is evaluating internal and external permanent CFO candidates.","Reaffirmed Q1 and full FY2025 guidance as disclosed in May 23, 2024 earnings release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226289,"accession_number":"0001613103-24-000064","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Medtronic EVP and President of Global Regions Rob ten Hoedt to retire effective June 28, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rob ten Hoedt, EVP and President of Global Regions, notified retirement on June 1, 2024.","Retirement effective June 28, 2024; no successor named in the filing.","ten Hoedt oversaw Medtronic's global regional operations as a top executive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226288,"accession_number":"0001193125-24-152334","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Medtronic issues €3.0B in senior notes across four tranches; net proceeds ~€2.97B for general corporate purposes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €850M 3.650% notes due 2029, €850M 3.875% due 2036, €600M 4.150% due 2043, €700M 4.150% due 2053.","Net proceeds of ~€2.97B after underwriting discount and expenses.","Proceeds to be used for general corporate purposes, may include repayment of commercial paper and other debt.","Notes fully and unconditionally guaranteed by Medtronic plc and Medtronic Global Holdings S.C.A.","Financial impact already reflected in FY2025 adjusted EPS guidance announced May 23, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226287,"accession_number":"0001613103-24-000058","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic reports Q4 FY24 revenue $8.59B, organic growth 5.4%; FY25 EPS guidance $5.40-$5.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS $0.49, non-GAAP $1.46; FY24 GAAP diluted EPS $2.76, non-GAAP $5.20.","FY24 revenue $32.4B (+3.6% reported, +5.2% organic); Q4 revenue $8.59B (+0.5% reported, +5.4% organic).","FY25 guidance: organic revenue growth 4%-5%; non-GAAP EPS $5.40-$5.50 (4-6% growth).","Dividend increased to $0.70 quarterly ($2.80 annual), 47th consecutive year of dividend increase.","Broad-based organic growth: Neuroscience +6.5%, Cardiovascular +4.0%, Medical Surgical +4.5%, Diabetes +11.1% in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":2.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":32364000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245334,"accession_number":"0001613103-24-000006","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Medtronic Q3 FY2024: Revenue $8.1B, GAAP EPS $0.99, raises FY24 guidance; exits ventilator business","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $8.089B, up 4.7% reported and 4.6% organic; GAAP EPS $0.99, non-GAAP EPS $1.30.","Raises FY24 organic revenue growth guidance to 4.75%-5% and non-GAAP EPS to $5.19-$5.21.","Exiting ventilator product line; combining PMRI into Acute Care & Monitoring unit.","EVP Robert J. White to leave April 26, 2024 due to organizational changes.","Diabetes revenue $640M, up 12.3%, U.S. returns to growth; CE Mark for MiniMed 780G with Simplera Sync."],"consensus_eps_estimate":null,"consensus_eps_actual":2.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":23775000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262788,"accession_number":"0001613103-23-000152","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Medtronic terminates acquisition of EOFlow due to multiple breaches","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Terminated share purchase, subscription, and tender agreements with EOFlow Co. Ltd. (KOSDAQ: 294090) on Dec 6, 2023.","Termination based on multiple breaches by EOFlow under the agreements; no termination fee payable.","Deal originally announced May 25, 2023; minimum tender condition and regulatory clearances were pending.","Medtronic reaffirms FY2024 adjusted EPS guidance provided Nov 21, 2023; termination has no impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262787,"accession_number":"0001613103-23-000144","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2023-11-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q2 FY24 revenue up 5.3% to $7.984B; GAAP EPS $0.68, non-GAAP $1.25; raises FY24 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.984B, +5.3% reported / +5.0% organic; GAAP net income $909M ($0.68 EPS) +113%; non-GAAP EPS $1.25.","Cardiovascular revenue $2.923B (+5.9%); Neuroscience $2.288B (+4.7%); Medical Surgical $2.142B (+7.0%); Diabetes $610M (+9.7%).","Raises FY24 organic revenue growth guidance to 4.75% (from 4.5%) and non-GAAP EPS guidance to $5.13–$5.19 (from $5.08–$5.16).","FDA approvals for Aurora EV-ICD and Symplicity Spyral RDN; CE Marks for Evolut FX TAVR, Simplera CGM, PulseSelect PFA."],"consensus_eps_estimate":null,"consensus_eps_actual":1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":15686000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262786,"accession_number":"0001613103-23-000132","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Medtronic shareholders approve 2024 ESPP (30M shares); directors re-elected with notable dissent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2024 Employee Stock Purchase Plan approved; 30M ordinary shares authorized; first purchase period Jan 1, 2024.","All 11 director nominees re-elected; O'Leary (107M against) and Powell (102M against) faced largest opposition.","PwC ratified as FY2024 auditor: 1.06B for, 101.7M against; executive compensation advisory approved: 968M for, 68.9M against.","Shareholders approved renewal of authority to issue shares, opt out of pre-emption rights, and authorize overseas share repurchases.","2014 ESPP to terminate after Dec 31, 2023 purchase period; no new periods under that plan after 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279982,"accession_number":"0001613103-23-000117","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q1 revenue $7.7B (+6% organic); raises FY24 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.70B, +4.5% reported, +6.0% organic; GAAP EPS $0.59 (-16%), non-GAAP EPS $1.20 (+6%).","FY24 organic revenue growth guidance raised to 4.5% (from 4.0-4.5%); non-GAAP EPS guidance raised to $5.08-$5.16 (from $5.00-$5.10).","All four segments delivered 6% organic growth: Cardiovascular +6.2%, Neuroscience +5.6%, Medical Surgical +6.1%, Diabetes +6.3%.","U.S. launches commenced for MiniMed 780G system and Micra AV2/VR2 leadless pacemakers.","Management cites broad strength and improved fundamentals; raises guidance based on Q1 outperformance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":7702000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298486,"accession_number":"0001613103-23-000043","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medtronic appoints Honeywell CFO Greg Lewis to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 11 to 12; Greg Lewis appointed effective June 26, 2023.","Lewis is SVP & CFO of Honeywell; will serve on Audit and Finance & Financial Risk Committees.","He receives standard non-employee director compensation per company policy.","CEO Geoff Martha cites Lewis's financial leadership across industries as asset for Medtronic's transformation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298485,"accession_number":"0001613103-23-000032","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q4 revenue beats at $8.5B (+5.6%); raises dividend to $0.69 quarterly","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $0.88 (-20% YoY); non-GAAP EPS $1.57 (+3%), ahead of expectations.","FY23 revenue $31.2B (-1.4% reported, +2.1% organic); FY organic growth guided 4.0-4.5%.","Dividend increased to $0.69/share quarterly ($2.76 annual); 46th consecutive annual increase.","Announced definitive agreement to acquire EOFlow Co. Ltd. (EOPatch tubeless insulin pump).","FY24 non-GAAP EPS guidance $5.00-$5.10; revenue positively impacted by FX ~$110-210M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":31227000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318693,"accession_number":"0001193125-23-085642","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Medtronic issues $2B in senior notes to refinance JPY term loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1B of 4.250% Senior Notes due 2028 and $1B of 4.500% Senior Notes due 2033.","Net proceeds of ~$1.98B to prepay portion of ¥297B (~$2.3B) JPY term loan.","Notes fully and unconditionally guaranteed by Medtronic plc and Medtronic, Inc.","Interest expense impact from offering and related transactions expected immaterial.","Underwriters include Barclays, J.P. Morgan, and Mizuho Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318692,"accession_number":"0001613103-23-000015","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Medtronic clarifies false redemption notice for 0.000% Senior Notes due 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Third party erroneously sent redemption notice for Medtronic Luxco's 0.000% Senior Notes due 2025 to Bloomberg and other data providers.","Medtronic Luxco has not issued a notice of redemption for these notes.","Erroneous communication occurred on March 9, 2023 and was broadly disseminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318691,"accession_number":"0001613103-23-000013","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Medtronic sets 2023 AGM for Oct 19; record date Aug 25; proposal deadlines revised","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2023 Annual General Meeting will be held on Thursday, October 19, 2023.","Record date for shareholder voting is close of trading on NYSE, Friday, August 25, 2023.","Deadline for Rule 14a-8 shareholder proposals: close of business Dublin, May 10, 2023.","Deadline for non-Rule 14a-8 proposals (including director nominations): July 21 to Aug 30, 2023.","Submissions must be sent to registered office in Dublin, Attn: Company Secretary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318690,"accession_number":"0001613103-23-000003","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q3 FY2023 revenue $7.73B (+4.1% organic), non-GAAP EPS $1.30, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.727B flat as reported, +4.1% organic; GAAP EPS $0.92 (-16%), non-GAAP EPS $1.30 (-4%), both ahead of expectations.","Cardiovascular +7% organic, Neuroscience +7% organic; Medical Surgical -2% organic (ex-ventilator/China +3%).","FY2023 non-GAAP EPS guidance raised to $5.28-$5.30 from $5.25-$5.30; Q4 organic revenue growth expected 4.5-5.0%.","Planned separations: Respiratory/Patient Monitoring (H2 FY2024) and Renal Care Solutions with DaVita (Q4 FY2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":22682000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336909,"accession_number":"0001613103-22-000066","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Medtronic shareholders elect all 11 director nominees, approve all proposals at 2022 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Each of 11 director nominees elected with 90-99% of votes cast (excluding broker non-votes).","Ratification of PwC as independent auditor for FY2023 passed with 92.2% of votes cast.","Advisory say-on-pay approved with 92.7% of votes cast (ex. broker non-votes).","Authority to issue shares, opt out of pre-emption, and overseas share purchases all approved with >97% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336908,"accession_number":"0001613103-22-000058","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2022-11-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q2 FY2023 revenue down 3%; lowers FY2023 EPS guidance to $5.25-$5.30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.585B, organic growth +2%; GAAP EPS $0.32 (down 67%), non-GAAP EPS $1.30 (down 2%).","FY2023 non-GAAP EPS guidance cut to $5.25-$5.30; H2 organic revenue growth expected 3.5%-4.0%.","Tax reserve adjustment of $764M from U.S. Tax Court opinion weighed on GAAP earnings.","Segment organic growth: Cardiovascular +4%, Medical Surgical -3%, Neuroscience +5%, Diabetes +3%.","CEO cites slower procedure/supply recovery; executing cost reductions and supply chain improvements."],"consensus_eps_estimate":null,"consensus_eps_actual":1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":14955000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354298,"accession_number":"0001193125-22-248112","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2022-09-21T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Medtronic issues €3.5B senior notes in four tranches to refinance near-term debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €500M 2.625% notes due 2025, €1B 3.000% due 2028, €1B 3.125% due 2031, €1B 3.375% due 2034.","Net proceeds ~€3.47B; to repay outstanding 0.00% notes due 2022, 0.375% and 0.00% notes due 2023.","Notes are senior unsecured obligations guaranteed by Medtronic plc and Medtronic, Inc.","Offering closed Sep 21, 2022; impact reflected in FY2023 adjusted EPS guidance reiterated Aug 23."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354297,"accession_number":"0001613103-22-000034","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2022-08-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q1 FY2023 revenue $7.37B (-4% organic) beats guidance; non-GAAP EPS $1.13 in line","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.70 (+25% YoY); non-GAAP diluted EPS $1.13 (-17% YoY), in line with expectations.","Revenue $7.371B, down 8% as reported (-4% organic), ahead of guidance; organic excludes $351M FX and $20M Intersect ENT.","Cardiovascular -1% organic, Medical Surgical -9% organic, Neuroscience -2% organic, Diabetes flat organic.","FY2023 guidance reiterated: organic revenue growth 4-5%, non-GAAP EPS $5.53-$5.65; FX headwind raised to $1.4-$1.5B.","Strength in Pacing (mid-teens Micra), Core Spine in US, CGM in Europe; ventilators declined low-fifties."],"consensus_eps_estimate":null,"consensus_eps_actual":0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":7371000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372247,"accession_number":"0001613103-22-000027","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2022-06-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medtronic appoints Lidia Fonseca to board, effective June 27, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 10 to 11 directors; Fonseca appointed as independent director.","Fonseca is EVP, Chief Digital & Technology Officer at Pfizer with 30+ years healthcare IT experience.","She will serve on Compensation and Science & Technology Committees.","At Pfizer she led digital acceleration of COVID-19 vaccine and advanced analytics platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372246,"accession_number":"0001613103-22-000016","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Medtronic posts FY22 rev +5%, Q4 adj EPS +2%; hikes dividend 8%, forms kidney JV with DaVita","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY22 revenue $31.686B, +5% reported and organic; Q4 revenue $8.1B, -1% reported, +1% organic.","Q4 GAAP diluted EPS $1.10 (+10%), non-GAAP diluted EPS $1.52 (+2%); FY22 GAAP diluted EPS $3.73 (+40%).","Quarterly dividend raised to $0.68 from $0.63 (+8%); annual $2.72; 45th consecutive year of increases.","Medtronic and DaVita form equally-owned kidney device JV; Medtronic contributes RCS ($325M FY22 rev). DaVita pays up to $400M value. Close expected calendar 2023.","FY23 guidance issued; no material adjusted EPS impact from JV in current or near-term fiscal years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372245,"accession_number":"0001193125-22-135320","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2022-05-02T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Medtronic enters ¥300B term loan; to redeem $2.27B in senior notes due 2025/2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered into a ¥300B (approx. $2.3B) 364-day unsecured term loan with Mizuho Bank at TIBOR+0.40%.","Proceeds to redeem $1.9B of Medtronic Inc. 3.500% notes due 2025 and $368M of Medtronic Luxco 3.350% notes due 2027.","Redemption dates: May 17, 2022 for 2027 notes; June 1, 2022 for 2025 notes.","Expects transactions to benefit FY2023 interest expense, partly offset by higher U.S. tax and global rates.","Will provide FY2023 guidance on upcoming FY2022 Q4 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391104,"accession_number":"0001613103-22-000006","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q3 FY2022 revenue flat at $7.8B; GAAP EPS $1.10 (+17%), non-GAAP EPS $1.37 (+6%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.763B flat YoY; organic growth 2%; COVID-19 impact on U.S. procedure volumes.","GAAP diluted EPS $1.10 (+17%); non-GAAP diluted EPS $1.37 (+6%), a penny above consensus.","Q4 guidance: organic revenue growth ~5.5%; non-GAAP EPS $1.56-$1.58.","Diabetes segment revenue down 7% as reported (-5% organic) driven by U.S. declines.","Cardiovascular up 3% organic; Medical Surgical up 1% organic; Neuroscience up 2% organic."],"consensus_eps_estimate":null,"consensus_eps_actual":2.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":23597000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409241,"accession_number":"0001613103-21-000070","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2021-12-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chief Medical & Scientific Officer Richard Kuntz to retire April 29, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Kuntz notified Medtronic on Dec 14, 2021 of retirement effective April 29, 2022.","Kuntz served as SVP and Chief Medical & Scientific Officer and on executive committee since 2005.","He leaves after over 15-year tenure at Medtronic and 40-year career as interventional cardiologist.","Filing does not name a successor or interim replacement for the role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409240,"accession_number":"0001613103-21-000067","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2021-12-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Medtronic Diabetes receives FDA warning letter; lowers Diabetes revenue guidance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA warning letter dated Dec 9 for Northridge, CA facility following July 2021 inspection related to MiniMed 600 series pump and controller recalls.","No change to total company organic revenue growth or adjusted EPS guidance for Q3 or FY2022.","Diabetes organic revenue now expected high-single-digit decline Q3 FY2022 (prev. mid-single-digit); mid-single-digit for FY2022 (prev. low-single-digit).","Preliminary FY2023 total company revenue impact modeled at less than 0.5pp to ~1pp of growth; full guidance on Q4 FY2022 call.","Company applying cross-company resources and external experts to address FDA observations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409239,"accession_number":"0001613103-21-000065","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2021-12-14T23:59:59+00:00","items":["1.01","5.07","9.01"],"status":"ready","headline":"Medtronic amends credit facility extending maturity to Dec 2026 and reducing borrowing costs","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended credit facility maturity from Dec 12, 2025 to Dec 12, 2026; removed cap on future extensions.","Reduced interest rate margins to 0.50%-1.00% over LIBOR and commitment fee to 0.045%-0.090% per annum.","Replaced LIBOR benchmarks for GBP, JPY, and EUR with successor rates due to LIBOR cessation.","Shareholders approved 2021 Long Term Incentive Plan and authorized overseas share repurchases.","All 10 directors re-elected; say-on-pay passed with 90.3% support; auditor ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409238,"accession_number":"0001613103-21-000058","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2021-11-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q2 FY2022 revenue $7.85B (+2% organic), non-GAAP EPS $1.32; lowers FY revenue growth view","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.847B (+3% reported, +2% organic); GAAP EPS $0.97, non-GAAP EPS $1.32.","Organic growth: Cardiovascular +3%, Medical Surgical flat (ex-ventilators +6%), Neuroscience +3%, Diabetes +1%.","Lowers FY22 organic revenue growth guidance to 7-8% from ~9% due to COVID-19 and labor shortages.","Reiterates FY22 non-GAAP EPS guidance $5.65-$5.75; FX revenue benefit reduced to $0-50M from $100-200M.","Diabetes pump sales grew high-teens US, low-twenties international; CGM sales low-single digits."],"consensus_eps_estimate":null,"consensus_eps_actual":1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":15835000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409237,"accession_number":"0001613103-21-000047","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2021-10-15T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Medtronic SPYRAL HTN-ON MED study DSMB recommends trial continuation; full cohort follow-up expected H2 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB prespecified interim analysis recommends ON MED clinical trial enrollment continue until full sample size of 260 patients is reached.","Full cohort follow-up expected in H2 2022; trial powered to detect statistically significant therapeutic benefit at final analysis.","Medtronic reiterates FY2022 revenue and EPS guidance; long-range plan of 5%+ organic revenue growth and 8%+ adjusted EPS growth unchanged.","Company projects global renal denervation market exceeding $500M by 2026 and $2-3B by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428166,"accession_number":"0001193125-21-269378","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2021-09-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Medtronic updates SPYRAL HTN-ON MED study timeline; interim analysis in late October","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Prespecified interim look at ON MED study data by independent monitoring board scheduled for late October.","If primary endpoint achieves statistical significance, trial investigators can present at TCT in early November.","ON MED study will not be on TCT late-breaking clinical trial agenda due to late October data timing.","Company working with CRF to ensure data is featured at TCT if endpoint met; enrollment will cease if significant.","If primary endpoint not significant at interim, enrollment will continue to full predefined sample size."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428165,"accession_number":"0001613103-21-000037","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2021-08-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q1 FY22 revenue $7.99B (+23% reported), non-GAAP EPS $1.41, beats expectations; raises FY22 EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.987B, up 23% reported and 19% organic; GAAP EPS $0.56, non-GAAP EPS $1.41.","Cardiovascular revenue $2.89B (+15% organic); Medical Surgical $2.32B (+25% organic); Neuroscience $2.20B (+26% organic).","Diabetes revenue $572M declined 3% organic; U.S. consumables and CGM sales fell mid-teens.","FY22 organic revenue growth reiterated at ~9%; non-GAAP EPS guidance raised to $5.65-$5.75 from $5.60-$5.75.","CEO Geoff Martha cites procedure recovery and share gains; company repurchasing shares and increasing R&D spend."],"consensus_eps_estimate":null,"consensus_eps_actual":0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":7987000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":97042452750.73598,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-24T23:59:59+00:00|428165"}